Hørsholm, Denmark, 6 June 2026 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that the Annual Report for the financial year 2025 has been published. The Annual Report is available as an attachment to this press release and can be accessed on the Company’s website at: https://investor.expres2ionbio.com/financial-reports/
The Annual Report provides a comprehensive overview of ExpreS2ion’s operational activities during 2025 and includes additional information regarding the Company’s full-year 2025 financial results. While the financial figures are consistent with those previously disclosed in the year-end report published in February 2026, the Annual Report contains expanded financial note disclosures and additional context on strategic and operational developments during the year.
The Swedish version of the Annual Report has been reviewed by the Company’s auditors, as confirmed in the Auditor’s Report included at the end of the document. In the event of discrepancies between the Swedish and English versions, the Swedish version shall prevail.
Certified Adviser
Redeye Nordic Growth AB
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Keith Alexander, CFO
E-mail: investor@expres2ionbio.com
The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company’s news distributor, Modular Finance, at the publication of this press release.
About ExpreS2ion
ExpreS2ion is a biotechnology company focused on the development of innovative active immunotherapies and vaccines for cancer and infectious diseases. The company has developed the ExpreS2™ platform, a proprietary protein expression technology used across more than 500 recombinant protein and virus-like particle (VLP) projects spanning research, diagnostics, and therapeutic development. Proteins produced using the ExpreS2 platform are being evaluated in multiple clinical programmes worldwide. The platform has also been applied in partnered development programmes that have progressed into late-stage clinical evaluation, including Phase III studies that have met their primary endpoints. The platform, marketed as GlycoX-S2™, includes functionally modified glycosylation variants designed to enhance immunogenicity and pharmacokinetics. ExpreS2ion develops novel VLP-based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. ExpreS2ion Biotech AB is listed on Nasdaq First North Growth Market. For additional information, please visit www.expres2ionbio.com.